Viewing Study NCT04649359

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:35 PM
Ignite Modification Date: 2026-02-03 @ 4:04 PM
Study NCT ID: NCT04649359
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-02
First Post: 2020-11-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Sponsor: Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myeloma View
None Multiple Myeloma View
None relapsed Multiple Myeloma View
None refractory Multiple Myeloma View
None PF-06863135 View
None BCMA View
None bispecific View
None bispecific antibody View
None BCMA-CD3 bispecific View
None Elranatamab View
None MagnetisMM-3 View